SCOTTSDALE, Ariz. Sept. 28, 2011 TGen Drug Development (TD2) won a Fast Lane award from the Arizona BioIndustry Association (AZBio) for promoting the economic development of Arizona biosciences.
TD2, a subsidiary of the Translational Genomics Research Institute (TGen), provides world-class clinical and regulatory expertise to biopharmaceutical companies using cutting-edge technology to minimize the risks in cancer drug development. TD2 works to shorten the development cycles for anti-cancer agents and improve their success rates.
"TD2 is at the forefront of helping pharmaceutical companies navigate the regulatory system to get the safest, most effective compounds as quickly as possible to the patients who need them," said Dr. Stephen Gately, President and Chief Scientific Officer of TD2. "This award not only recognizes the good work of TD2, but is reflective of all the advancements of TGen, and of our collaborators."
Another recipient of a Fast Lane award is Flagship Biosciences, which provides tissue analysis services. Earlier this year, the Flagstaff company forged a strategic alliance with TD2 to help speed new drugs safely into human testing, where they can quickly benefit cancer patients.
Since 2002, according to Battelle: jobs in Arizona's bioscience industry grew 32 percent; the number of bioscience and related firms including research, manufacturing, testing, medical labs, and healthcare delivery systems grew 28 percent; and research partnerships with the National Institutes of Heath (NIH) increased 65 percent. Arizona bioscience organizations now generate $21 billion in annual revenues and $765 million in state and local taxes.
"These are measurable results from a community committed to working together to build a world-class research base, support commercialization efforts, and migrate the latest discoveries from the bench to the bedside in a manner that is both translational and transformational, " s
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute